Skip to content
Menu

60 Degrees Pharmaceuticals, Inc. SXTP

Full chart Compare
Set alert

Price alert · SXTP

All alert types
0.50 USD -0.04 (-7.05%)

Regular-session close

0.50 0.00 0.00%

After hours · Nov 19, 5:24 PM ET

0.50 Day range 0.5165
0.46 52-week range 8.62
YTD
-75.37%
1 year
-88.10%

5D +0.0232 (+4.59%)

0.48000.50000.52000.5400WedThuFriMonTue0.5281
Market cap
2.24M
Revenue (ttm)
441.25K
EPS (ttm)
-5.34
Shares out
2.30M
Forward P/E
-0.65
YTD return
-75.37%
1-year return
-88.10%
50-day average
1.09
Volume
22.28K
Avg volume
406.73K
Open
0.50
Previous close
0.5379
Day's range
0.50 – 0.5165
52-week range
0.46 – 8.62
Analysts
Buy
Price target
3.40 (+580.0%)

Key statistics

200-day average
2.14
Enterprise value
9.95M
Price / sales
6.04
Revenue growth
100.60%
Free cash flow
-1.06M
Total cash
1.58M
Total debt
157.44K
Short % of float
2.12%

Fundamental scorecard

4 of 25 checks passed on SXTP’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 1 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
SXTP Revenue — quarterly 233.24K
SXTP Net income — quarterly -2.56M
SXTP EPS — quarterly -0.75

Earnings

SXTP recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 2024-0.60-0.93-0.33-55.00%
Aug 14, 2024Jun 1, 2024-3.96-4.23-0.27-6.82%
Aug 14, 2024Jun 1, 2024-3.96———
May 15, 2024Mar 1, 2024-1.92———
May 15, 2024Mar 1, 2024-1.920.36+2.28+118.75%
Apr 1, 2024Dec 1, 2023-3.24-5.28-2.04-62.96%

Upgrades / downgrades

SXTP analyst upgrades and downgrades
DateFirmActionFromTo
Dec 23, 2024HC Wainwright & Co.reitNeutralNeutral
Dec 11, 2024HC Wainwright & Co.reitNeutralNeutral
Nov 15, 2024HC Wainwright & Co.reit—Neutral
Sep 13, 2024HC Wainwright & Co.reit—Neutral
Aug 15, 2024HC Wainwright & Co.reit—Neutral
Jun 6, 2024HC Wainwright & Co.reit—Neutral

About 60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on SXTP — it syncs with the Stock Master app.

Insider holders

SXTP insider holders
InsiderRelationLatest transactionDateShares held
ALLEN CHARLES WDirectorConversion of Exercise of derivative securityMay 15, 202414,000
DOW GEOFFREY SChief Executive OfficerConversion of Exercise of derivative securityMay 15, 2024762,625
FIELD PAULDirectorConversion of Exercise of derivative securityMay 15, 202414,000
KNIGHT THERAPEUTICS, INC.Beneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityJul 27, 20230
MILLER TYRONEChief Financial OfficerStock Award(Grant)May 15, 2024176,928
TOOVEY STEPHENDirectorStock Award(Grant)May 15, 202414,000

Institution ownership

SXTP institution ownership
Holder% heldSharesValueReported
Virtu Financial LLC0.55%12,67814.71KSep 29, 2024
Citadel Advisors Llc0.44%10,09511.71KSep 29, 2024
National Bank of Canada/FI0.17%4,0004.64KSep 29, 2024
UBS Group AG0.14%3,3113.84KSep 29, 2024
Tower Research Capital LLC (TRC)0.06%1,4731.71KSep 29, 2024
Safe Harbor Fiduciary, LLC 0.06%1,3751.59KSep 29, 2024

Fund ownership

SXTP fund ownership
Holder% heldSharesValueReported
Fidelity Extended Market Index Fund0.17%3,8754.49KOct 30, 2024
Fidelity Series Total Market Index Fund0.09%2,1372.48KOct 30, 2024
Vanguard Extended Market Index Fund0.03%588682Sep 29, 2024